Detection of Various Cancer Types for Screening and Diagnosis through Blood Samples with Epigenetic Biomarkers Panels

Informacje na temat projektu

EPICHECK

Identyfikator umowy o grant: 696425

DOI 10.3030/696425

Projekt zamknięty

Data podpisania przez KE 30 Września 2015

Data rozpoczęcia 1 Października 2015

Data zakończenia 31 Marca 2016

Finansowanie w ramach

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Koszt całkowity € 71 429,00

Wkład UE € 50 000,00

Koordynowany przez

NUCLEIX LTD
Israel

Cel

Nucleix developed a revolutionary platform for the development of Methylation Bio-markers and Bio-Marker panels for screening (early detection of disease) and diagnosis based on epigenetic markers. The platform identifies changes in specific methylation locations of DNA extracted from body fluids such as – urine, blood, stools and sputum. A Bio-Markers panel goal is to distinguish between sick and healthy individuals. The company’s expertise include the identification of the specific loci, comprising a panel of markers that can work in multiplex and generate highly accurate test. Nucleix technology was proven to be extremely sensitive and specific in its first application.
Nucleix focuses initially on the field of cancer detection and screening. Cancer cost the EU €126 billion in 2009, which was 1.07% of EU GDP. 2.45m People in the EU were diagnosed with cancer in 2008, when 1.23 million people in the EU died from cancer in 2008. This is one of the most significant public health issues in the world and in the EU. Nucleix first product, Bladder EpiCheck is a urine test for the detection of Bladder Cancer. It is aimed for monitoring bladder cancer patients as this is a disease with high recurrence rate and requires tight surveillance. This product will be launched in Q4 of 2015. The test is based on a panel of 15 non-overlapping Methylation markers at loci that were identified, developed and owned by the company. This product which has better sensitivity and specificity than any other non-invasive test is a proof of the company’s ability to translate its technology to applicable products.
The company plans to develop EPICHECK - diagnostic kits using multi-loci panel of markers, for the detection and screening of lung cancer and colorectal cancer in blood samples – which is the subject of this applications.
EPICHECK will be launched rapidly, and will provide revenues of over 320m Euro in its 5th year of commercial activities.

Dziedzina nauki

• medical and health sciences › clinical medicine › oncology › bladder cancer
• engineering and technology › medical engineering › medical laboratory technology › laboratory samples analysis
• natural sciences › biological sciences › genetics › epigenetics

Program(-y)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Temat(-y)

• PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Zaproszenie do składania wniosków

H2020-SMEInst-2014-2015

Zobacz inne projekty w ramach tego zaproszenia

Szczegółowe działanie

H2020-SMEINST-1-2015

System finansowania

SME-1 - SME instrument phase 1

Koordynator

NUCLEIX LTD

• Wkład UE netto: € 50 000,00
• Adres: 3 PEKERIS STREET ; 7670203 REHOVOT ; Izrael
• MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak:
  Rodzaj działalności
  Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Rodzaj działalności: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Koszt całkowity: € 71 429,00